Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 5/2016

Ausgabe 5/2016

Inhaltsverzeichnis ( 15 Artikel )

14.05.2016 | PRECLINICAL STUDIES | Ausgabe 5/2016

The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line

Raffaele Pezzani, Beatrice Rubin, Loris Bertazza, Marco Redaelli, Susi Barollo, Halenya Monticelli, Enke Baldini, Caterina Mian, Carla Mucignat, Carla Scaroni, Franco Mantero, Salvatore Ulisse, Maurizio Iacobone, Marco Boscaro

18.05.2016 | PRECLINICAL STUDIES | Ausgabe 5/2016

In vitro and in vivo antineoplastic and immunological effects of pterocarpanquinone LQB-118

Eduardo J. Salustiano, Matheus L. Dumas, Gabriel G. Silva-Santos, Chaquip D. Netto, Paulo R. R. Costa, Vivian M. Rumjanek

29.07.2016 | PRECLINICAL STUDIES | Ausgabe 5/2016 Open Access

Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report

Magdalena Kusaczuk, Rafał Krętowski, Anna Stypułkowska, Marzanna Cechowska-Pasko

25.05.2016 | PHASE I STUDIES | Ausgabe 5/2016 Open Access

Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors

Cynthia M. Nijenhuis, Edward Hellriegel, Jos H. Beijnen, Diane Hershock, Alwin D. R. Huitema, Luc Lucas, Marja Mergui-Roelvink, Mihaela Munteanu, Laura Rabinovich-Guilatt, Philmore Robertson Jr., Hilde Rosing, Ofer Spiegelstein, Jan H. M. Schellens

11.06.2016 | PHASE I STUDIES | Ausgabe 5/2016

Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)

Amy Prawira, Irene Brana-Garcia, Anna Spreafico, Andrew Hope, John Waldron, Albiruni R. Abdul Razak, Eric X Chen, Raymond Jang, Brian O’Sullivan, Meredith Giuliani, Andrew Bayley, John Cho, Lisa Wang, Bayardo Perez-Ordonez, Ilan Weinreb, Lillian L. Siu, Aaron R Hansen

01.09.2016 | PHASE I STUDIES | Ausgabe 5/2016 Open Access

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies

Kiyotaka Yoh, Toshihiko Doi, Hironobu Ohmatsu, Takashi Kojima, Hideaki Takahashi, Yoshitaka Zenke, Volker Wacheck, Sotaro Enatsu, Takashi Nakamura, Kellie Turner, Kazunori Uenaka

01.07.2016 | PHASE I STUDIES | Ausgabe 5/2016 Open Access

Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors

Hidenori Mizugaki, Noboru Yamamoto, Haruyasu Murakami, Hirotsugu Kenmotsu, Yutaka Fujiwara, Yoshimasa Ishida, Tomohisa Kawakami, Toshiaki Takahashi

16.07.2016 | PHASE I STUDIES | Ausgabe 5/2016

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

Lee S. Rosen, Patricia LoRusso, Wen Wee Ma, Jonathan W. Goldman, Amy Weise, A. Dimitrios Colevas, Alex Adjei, Salim Yazji, Angela Shen, Stuart Johnston, Hsin-Ju Hsieh, Iris T. Chan, Branimir I. Sikic

12.07.2016 | PHASE I STUDIES | Ausgabe 5/2016

A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia

Karen W. L. Yee, Hsiao-Wei T. Chen, David W. Hedley, Sue Chow, Joseph Brandwein, Andre C. Schuh, Aaron D. Schimmer, Vikas Gupta, Deborah Sanfelice, Tara Johnson, Lisa W. Le, Jamie Arnott, Mark R. Bray, Carolyn Sidor, Mark D. Minden

27.06.2016 | PHASE II STUDIES | Ausgabe 5/2016

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

Giorgio Scagliotti, Jin Hyoung Kang, David Smith, Richard Rosenberg, Keunchil Park, Sang-We Kim, Wu-Chou Su, Thomas E. Boyd, Donald A. Richards, Silvia Novello, Scott M. Hynes, Scott P. Myrand, Ji Lin, Emily Nash Smyth, Sameera Wijayawardana, Aimee Bence Lin, Mary Pinder-Schenck

23.06.2016 | PHASE II STUDIES | Ausgabe 5/2016

Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites

Naminatsu Takahara, Hiroyuki Isayama, Yousuke Nakai, Hironori Ishigami, Sohei Satoi, Suguru Mizuno, Hirofumi Kogure, Saburo Matsubara, Natsuyo Yamamoto, Hironori Yamaguchi, Minoru Tada, Joji Kitayama, Toshiaki Watanabe, Kazuhiko Koike

29.07.2016 | REVIEW | Ausgabe 5/2016

The renal effects of ALK inhibitors

Hassan Izzedine, Rania Kheder El-Fekih, Mark A. Perazella

02.06.2016 | SHORT REPORT | Ausgabe 5/2016

Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy

Farzan Kianersi, Heshmatollah Ghanbari, Zahra Naderi Beni, Afsaneh Naderi Beni

26.05.2016 | SHORT REPORT | Ausgabe 5/2016

Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors

Noura Benslama, Julien Bollard, Cécile Vercherat, Patrick Massoma, Colette Roche, Valérie Hervieu, Julien Peron, Catherine Lombard-Bohas, Jean-Yves Scoazec, Thomas Walter

22.06.2016 | SHORT REPORT | Ausgabe 5/2016

Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine–induced apoptosis in neuroblastoma cells

Jennifer C. Lennon, Stefania Butini, Giuseppe Campiani, Anne O’Meara, D. Clive Williams, Daniela M. Zisterer

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise